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RESPONSE TO CORRESPONDENCE FROM PROFESSOR RADOSTITS
Fluoroquinolone-resistant Campylobacter
infections and animal drug use
The provocative article by Professor Radostits
poses several important questions regarding re-
lationships between the use of ﬂuoroquinolone
antimicrobials in poultry and the world-wide emer-
gence of strains of campylobacter exhibiting re-
sistance to this group of antimicrobials.1 In par-
ticular the author has drawn attention to possible
anomalies in the data of Endtz and colleagues,
that demonstrated an increase in resistance to ﬂu-
oroquinolones from 0% in 1982 to 11% in 1989 in
human isolations of Campylobacter jejuni in the
Netherlands following the licensing of this group
of antimicrobials for use in poultry, cattle and pigs
in 1987.2 Radostits has questioned the validity of
these and other data. This is because strains of C.
lari are intrinsically resistant to nalidixic acid and
resistance to this antimicrobial was used in many
laboratories as a preliminary screen for differen-
tiating between Campylobacter lari and Campy-
lobacter jejuni/Campylobacter coli. By this logic,
strains with resistance to nalidixic acid were of-
ten classiﬁed as C. lari without recourse to further
tests. As all strains of Campylobacter spp. that ex-
hibit resistance to ﬂuoroquinolones are invariably
resistant to nalidixic acid, strains of C. jejuni with
such resistance may have been ‘missed’. On this
basis the conclusions of Endtz and colleagues re-
lating to ﬂuoroquinolone usage in food-producing
animals may be incorrect, and the 0% baseline of
ﬂuoroquinolone resistance in campylobacter in the
USA in 19913 may have been false.
Fortunately Endtz and colleagues were well
aware of this possibility. As they were unable
to distinguish between quinolone-resistant C.
coli and C. lari using conventional methods, a
range of additional tests were performed on all
quinolone-resistant strains tested in their study
and in addition, the results of identiﬁcation and
biotyping were conﬁrmed by the WHO Collabo-
rating Centre for Campylobacter Infections. By
these tests none of the quinolone-resistant strains
were identiﬁed as C. lari. Thus, although the pos-
sibility that a very small number of strains of C.
jejuni/C. coli isolated from poultry and humans
in the Netherlands between 1982 and 1989 may
have been missed cannot be totally excluded, the
ﬁndings of Endtz and colleagues are sound and the
conclusions perfectly justiﬁable. These results and
conclusions have subsequently been reinforced by
reports from numerous countries throughout the
world. Data for human isolates of C. coli and C. je-
juni from Denmark, the UK, the USA, Italy, Finland,
the Netherlands, France, Austria and Spain have
demonstrated increases in the incidence of resis-
tance to ﬂuoroquinolones from <1% to between
10% (UK) and 80% (Spain) following the licensing
of such antibiotics for use in food animals, pre-
dominantly poultry, in the respective countries in
the 1980s and 1990s.4 More recent data from the
UK have shown an increase of the incidence of
ﬂuoroquinolone-resistant isolates of C. jejuni from
humans from 10% in 1993–96 to 21% in 2003. Again,
the use of ﬂuoroquinolones in poultry was consid-
ered an important contributory factor, although
foreign travel was also implicated in a signiﬁcant
number of infections.7
It is widely accepted that an important source
of campylobacter causing infections in humans
world-wide is poultry. The implications from studies
quoted above are that ﬂuoroquinolone resistance in
C. jejuni and C. coli from cases of human infection
in many countries and the use of ﬂuoroquinolones
in food animals, particularly poultry, are inextri-
cably linked. These conclusions are reinforced by
ﬁndings from Australia, a country that has not al-
lowed the use of ﬂuoroquinolones in food animals
and where domestically-acquired campylobacter
infections are susceptible to these antimicrobials.5
Thus, although increases in the occurrence of re-
sistance to ﬂuoroquinolones in isolations of campy-
lobacter from humans and the licensing/use of such
compounds in food animals and particularly poultry
is for the most part temporal, the conclusion that
such increases are linked to ﬂuoroquinolone usage
in this animal species is fully justiﬁable.
As Radostits points out, the contribution of for-
eign travel in the occurrence of ﬂuoroquinolone-
resistant strains of campylobacter from cases of in-
fection in humans cannot be overlooked. In a study
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in the USA reported in 1999, a signiﬁcant proportion
of patients infected with isolates with resistance
to ﬂuoroquinolones had acquired their infections
abroad.6 Similarly in the UK, 55% of campylobac-
ter infections acquired abroad in the period 1 April
2000 to 31 May 2001 were resistant to ciproﬂoxacin
compared with 10% of UK-acquired strains.7 More
recently, in the USA both eating poultry outside the
home and foreign travel have been identiﬁed as risk
factors for infections with ﬂuoroquinolone-resistant
campylobacter.8
However, what is not clear is whether patients
infected with ﬂuoroquinolone-resistant strains fol-
lowing foreign travel had acquired their infections
from contaminated poultry meat in the countries
visited, or resistance had arisen as a result of the
use of such antimicrobials in human medicine in
the countries concerned. For patients from the UK
the most commonly-visited foreign country was
Spain,7 where ﬂuoroquinolone-resistant campy-
lobacters are endemic in poultry and where 80%
of strains from cases of human infection in 2000
were ciproﬂoxacin-resistant.4 However, in a study
of patients from the USA who acquired their infec-
tions with ﬂuoroquinolone-resistant campylobacter
whilst in Thailand, where ﬂuoroquinolones are al-
legedly not used in poultry, prophylactic treatment
with ciproﬂoxacin for travellers’ diarrhoea may
have been an important contributory factor.9
It also should be realised that the use of ﬂu-
oroquinolone antimicrobials in food-production
animals and the appearance of resistance is not
conﬁned to campylobacter. In the UK, the appear-
ance and spread of muliple drug-resistant strains
of Salmonella enterica serotype Typhimurium
deﬁnitive phage type (DT) 104 (=DT104) with ad-
ditional decreased susceptibility to ciproﬂoxacin
was temporally linked to the licensing of ﬂu-
oroquinolone compounds for use in food pro-
duction animals in 1993.10 In 1999 the use of a
ﬂuoroquinolone-containing compound for the treat-
ment of cattle infected with multiple-resistant
DT104 was demonstrated to be an important factor
in the development of resistance to quinolones in
such strains, which subsequently caused over 100
infections in humans.11
The message from the above reports is that the
use of antimicrobials such as the ﬂuoroquinolones
is inextricably linked to the development of resis-
tance in target organisms. When the organisms are
zoonotic, and when the antimicrobials are used in
food animals, then such animals will eventually har-
bour resistant organisms capable of causing disease
in humans. Likewise, the use of antimicrobials such
as the ﬂuoroquinolones in human medicine will also
promote the development of resistance. When such
antimicrobials are used in an indiscriminate man-
ner, as for example for the prophylaxis of syndromes
such as traveller’s diarrhoea, then resistant organ-
isms will emerge and proliferate in the human host.
Retrospectively, the licensing of ﬂuoroquinolone
antimicrobials for use in food production animals
on a worldwide scale may have been unwise, as
such usage has undoubtedly resulted in the ap-
pearance and spread in food animals of strains of
campylobacter and salmonella capable of causing
disease in humans. However the indiscriminate use
of this important group of antimicrobials in human
medicine is also to be deplored, and has proba-
bly contributed not only to the high incidence of
ciproﬂoxacin-resistant campylobacter in Thailand,9
but also to the appearance and spread of strains of
S. typhi and S. paratyphi A with decreased suscep-
tibility to ciproﬂoxacin in several countries in the
Indian sub-continent.12 To combat antimicrobial
resistance in pathogens such as campylobacter and
salmonella, principles of prudent usage should be
applied at all times in both veterinary and human
medicine.
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